- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
| 04.11. | Kairos Pharma reports positive interim results for prostate cancer drug | 2 | Investing.com | ||
| 20.10. | Kairos Pharma, Ltd: Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting | 844 | Business Wire | Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage... ► Artikel lesen | |
| 15.10. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | Kairos Pharma stock rises after selection for ESMO Congress presentation | 2 | Investing.com | ||
| 07.10. | Kairos Pharma präsentiert Daten zu Prostatakrebs-Therapie auf ESMO-Kongress | 3 | Investing.com Deutsch | ||
| 07.10. | Kairos Pharma, Ltd: Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 | 333 | Business Wire | Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to... ► Artikel lesen | |
| 07.10. | Kairos Pharma, LTD. - 8-K, Current Report | 5 | SEC Filings | ||
| 22.09. | Kairos Pharma stock gains as H.C. Wainwright reiterates Buy rating | 1 | Investing.com | ||
| 18.09. | Kairos Pharma meldet vielversprechende Studiendaten zu Prostatakrebs-Therapie | 1 | Investing.com Deutsch | ||
| 18.09. | Kairos Pharma reports promising interim data for prostate cancer therapy | 3 | Investing.com | ||
| 18.09. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.09. | Kairos Pharma präsentiert erste Phase-1-Daten zu Lungenkrebs-Medikament auf Fachkonferenz | 2 | Investing.com Deutsch | ||
| 03.09. | Kairos Pharma to present initial phase 1 data for lung cancer drug at conference | 3 | Investing.com | ||
| 03.09. | Kairos Pharma, Ltd: Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025 | 271 | Business Wire | Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data... ► Artikel lesen | |
| 03.09. | Kairos Pharma, LTD. - 8-K, Current Report | 4 | SEC Filings | ||
| 15.08. | Interview: Kairos Pharma CEO John Yu on ENV105's potential & partnerships for growth | 3 | iNVEZZ.com | ||
| 12.08. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 28.07. | Kairos Pharma, LTD. - 10-K/A, Annual Report | 2 | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OLEMA PHARMACEUTICALS | 19,460 | 0,00 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| NUVATION BIO | 7,160 | 0,00 % | Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug | ||
| NUVALENT | 107,08 | +2,72 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| QIAGEN | 39,130 | +2,78 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 82,14 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Third Quarter 2025 Financial Results | SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,88 | 0,00 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| ARCUTIS BIOTHERAPEUTICS | 27,900 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,050 | 0,00 % | Mineralys Therapeutic: Aktie gibt nach umfangreichen Insiderverkäufen nach | ||
| ADMA BIOLOGICS | 15,950 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,940 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 36,500 | 0,00 % | Structure Therapeutics stock rating reiterated ahead of key trial data | ||
| PRAXIS PRECISION MEDICINES | 189,82 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,035 | 0,00 % | Is Recursion Pharmaceuticals a Meme Stock? | ||
| EDGEWISE THERAPEUTICS | 22,350 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| ARCELLX | 89,72 | -0,30 % | Arcellx stock initiated at Peerperform by Wolfe Research amid BCMA market competition |
Das Unternehmen KAIROS PHARMA LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,758 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAIROS PHARMA LTD finden Sie auf Wallstreet Online.